Trading Biotech Conferences: ASCO, ESMO, AAIC

The pattern is predictable and costly. A small oncology biotech presents at ASCO. Traders buy the stock the Thursday night before the presentation, expecting a Monday morning pop. They are 48 hours late. The abstract dropped that same Thursday at 5 PM, and the move happened in the first 15 minutes of Friday’s session. The entire trade is missed. Medical conferences are the second-biggest catalyst events in biotech after FDA decisions, but they are harder to trade because the data leaks in stages and the market reaction is faster. Here is how to position ahead of the pattern, not chase it.

The Conference Calendar: What Moves When

Not all conferences are equal. Each moves a specific sector and the calendar drives positioning windows.

Conference	Timing	Sector	Impact level
ASCO (American Society of Clinical Oncology)	Early June	Oncology	Highest. Moves more oncology stocks than any other event except FDA decisions.
ESMO (European Society for Medical Oncology)	October (Oct 23-27, 2026)	Oncology (European emphasis)	High. ASCO’s follow-up; data from Asia-Pacific and European trials.
AAIC (Alzheimer’s Association International Conference)	July	Neuroscience / Alzheimer’s	Highest for the sector. Every Alzheimer’s drug in development presents data here.
ASH (American Society of Hematology)	December	Hematology / blood cancers	High. CAR-T, bispecific antibodies, and gene therapies for blood disorders dominate.
AAN (American Academy of Neurology)	April	Neurology	Moderate. Parkinson’s, MS, epilepsy, and rare neurological diseases.
EASL (European Association for the Study of the Liver)	June	Liver disease	Moderate. NASH/MASH, hepatitis B functional cures, rare liver diseases.
ATS (American Thoracic Society)	May	Respiratory	Moderate. IPF, PAH, cystic fibrosis.

ASCO and AAIC are the two that can reprice entire sectors in a single weekend. ESMO and ASH are the second tier. The rest are niche events where individual stocks move, but they don’t produce sector-wide rotations.

Step 1: Track the Abstract Release Dates, Not the Presentation Dates

This is the most common mistake. The stock moves on abstract release day, not presentation day. Abstracts are published online 2-4 weeks before the conference. Titles of accepted regular abstracts for ESMO 2026 are expected online by July 17; late-breaking abstract titles by September 25. ASCO follows a similar cadence.

The sequence: (1) abstracts published online, typically on a Thursday afternoon, (2) stocks gap up or down within minutes, (3) oral presentations at the conference 2-4 weeks later occasionally add color but rarely move the stock again.

The “abstract-drop Monday” observation: if you’re reading the abstract on Monday morning, the move is already done. The stocks that moved moved on Thursday at 5:01 PM.

What to do: Mark the abstract release date on your calendar, not the conference date. For ESMO 2026, that’s late September for late-breakers (ESMO abstract schedule). Set price alerts at the abstract release time, not the presentation time.

Step 2: Sort Data by What Actually Moves Stocks

Not all data is equal. Here’s the hierarchy from highest-impact to lowest.

1. Overall survival (OS) beats everything. A statistically significant improvement in how long patients live is the gold standard. If a company reports a positive OS result, the stock moves and keeps moving.
2. Progression-free survival (PFS) is the next tier. Tumors growing slower is good, but it’s not the same as patients living longer. PFS wins move stocks, but the move is smaller and fades faster than OS moves.
3. Overall response rate (ORR) is the lowest efficacy tier. Tumor shrinkage matters, but only if it’s durable and translates to survival. An ORR headline without duration of response data is a red flag.

Trial design matters more than the endpoint alone: randomized Phase 3 data always beats single-arm Phase 2 data. A statistically significant result with a clinically meaningful magnitude (e.g., HR 0.65 with p<0.001) beats statistical significance with a marginal effect (e.g., HR 0.92 with p=0.04).

Bottom line: If a company at ASCO reports a randomized Phase 3 overall survival win with p<0.001, you buy. If they report a single-arm Phase 2 ORR with no comparator, you watch.

Step 3: Play the Pre-Conference Run-Up

Biotech stocks often rally 5-15% in the 4-6 weeks before major conferences. Investors position for positive data, and the “buy the rumor” effect kicks in. The pattern is consistent enough to trade.

The contrary trade: if a stock has run 30% into a conference on nothing but expectation, the setup is asymmetric in the wrong direction. A positive data readout typically adds 5-10%, but disappointing data could drop the stock 40%. The pre-conference run-up is a bet, not the trade itself.

What to do: Screen for the stocks presenting registrational data at the next major conference. If the stock has already rallied 20%+ in the month before abstract release, consider selling before the drop. The data needs to deliver a 50%+ efficacy signal to justify the price at that point.

Step 4: Read the Presentation Tier

Presentation slot matters. Plenary sessions get the most attention and produce the biggest moves. The hierarchy:

1. Plenary session (late-breaking abstract in the main hall). These are the headliners.
2. Oral presentation (invited talk in a session room). Still high-visibility.
3. Poster discussion (poster with a short oral presentation). Lower visibility, but investors still show up.
4. Poster only (a board in the exhibition hall). Lowest visibility.

A late-breaking abstract in a plenary session is the highest-impact presentation slot. The stock will move most on the abstract release, but the presentation can add a second move if the Q&A reveals new details.

What to do: When the abstract titles are released, scan for “Late-Breaking Abstract” and “Plenary Session.” Those are your trade candidates. Poster-only abstracts are noise.

Step 5: Trade the Post-Conference Drift

After a positive data readout and a strong initial pop, biotech stocks often drift down over the following 2-3 weeks. Conference tourists (investors who bought for the event) take profits and move on. The “buy on abstract, sell on presentation” pattern works because the initial pop prices in the best-case scenario, and reality sets in during the Q&A.

What to do: If you’re holding through the conference for a catalyst, set a sell order at the abstract release pop, not the presentation. If you’re buying after the conference, wait for the 2-3 week drift to settle before entering.

Step 6: The ESMO/ASH Calendar for H2 2026

For the rest of 2026, the two major conferences left are:

• ESMO 2026 (Oct 23-27, Madrid): Oncology. Late-breaking abstract titles expected online September 25. Stocks presenting registrational oncology data will move on that date.
• ASH 2026 (December): Hematology. Dates typically announced in mid-year. The same abstract-release rhythm applies.

Between now and ESMO, the positioning window opens in late August. Stocks presenting registrational data will start their pre-conference run-ups. Screen for companies that have confirmed late-breaking abstract acceptances.

Common Mistakes

1. Buying the stock the week of the conference. The move happened on abstract release day 2-4 weeks earlier. You’re buying after the information is priced in.
2. Trading the presentation, not the abstract. The presentation is theater. The abstract is the data. The market reacts to the abstract.
3. Confusing ORR with efficacy. A 40% response rate sounds good, but without duration of response, it’s an incomplete picture. Plenty of drugs with 40% ORR never reached an OS benefit in Phase 3.
4. Ignoring the trial design. Single-arm Phase 2 at a plenary session still isn’t randomized Phase 3. The conference prestige doesn’t change the evidence quality.
5. Holding through the conference without a plan. If you bought for the abstract release, sell on the pop. If you’re holding for the presentation, understand you’re betting on the Q&A, not the data.

Final Checklist

• Mark abstract release dates, not conference dates
• Sort the presenting stocks by data tier (OS > PFS > ORR; randomized Phase 3 > single-arm Phase 2)
• Check pre-conference run-up: has the stock already rallied 20%+ on expectation?
• Identify presentation tier: late-breaking abstract in plenary session or poster-only?
• Set sell orders at abstract release time, not presentation time
• Wait 2-3 weeks after the conference before re-entering on positive data

For more on reading the data itself, see how to decode clinical trial readouts and the 8-step Phase 3 check before trading. For the stocks presenting at each conference, the oncology sector catalyst calendar tracks every upcoming data readout.